AcuCort's Zeqmelit® Gains Traction in Nordic Market
AcuCort's innovative product Zeqmelit® sees positive reception in the Nordics, bolstered by a new order from Unimedic Pharma.
Sammanfattning
AcuCort's Zeqmelit® has been well-received in the Nordic market since its launch, with a recent order from Unimedic Pharma enhancing its financial outlook.
AcuCort AB, a pioneering company listed on the Spotlight Stock Market, has announced promising developments for its flagship product, Zeqmelit®, in the Nordic region. Since its launch in September 2024, Zeqmelit® has garnered enthusiastic support from the medical community, particularly during the allergy season when healthcare visits surge. This innovative oral film, which dissolves rapidly on the tongue, offers a convenient and effective treatment for severe allergic reactions, among other conditions.
In a recent update, AcuCort revealed a new order valued at EUR 60,385 from Unimedic Pharma, its Nordic distribution partner. This order underscores the growing demand for Zeqmelit® in the region and is expected to positively impact AcuCort’s financial performance. The collaboration with Unimedic Pharma has been instrumental, with their expertise and commitment significantly contributing to the product's success.
CEO Jonas Jönmark expressed optimism about the Nordic market's potential, highlighting the strong support from physicians and the strategic role of Unimedic Pharma in expanding Zeqmelit®'s reach. The recent order follows a previous one for the Danish market earlier in April 2025, indicating a sustained interest and demand for the product across the Nordics.
Given the positive market response and the strategic growth in the Nordic region, AcuCort presents a compelling case for investors. The company's innovative approach and strategic partnerships position it well for continued success. Investors might consider this a promising opportunity, especially as AcuCort continues to expand its market presence and enhance its product offerings.
In conclusion, with the current momentum and strategic market positioning, AcuCort's prospects appear bright. Investors are advised to hold their positions as the company continues to capitalize on its strengths and expand its footprint in the Nordic market.
Källa
Sammanfattning
Zeqmelit® was introduced in the Nordic region in September 2024 and has been well-received by the medical community. Unimedic Pharma, AcuCort's distribution partner in the Nordics, has placed a new order for the Nordic market. According to Jonas Jönmark, CEO of AcuCort, the Nordic market is experiencing strong growth, especially during the allergy season, with significant support from physicians. The order, valued at EUR 60,385, is expected to positively impact AcuCort's financial results. AcuCort previously received an order from Unimedic Pharma for the Danish market in April 2025. Zeqmelit® is a rapidly dissolving oral film containing dexamethasone, used for treating severe allergic reactions, croup in children, nausea during chemotherapy, and COVID-19 patients needing oxygen therapy. It is approved in Sweden, Denmark, Norway, and Finland, and AcuCort is listed on the Spotlight Stock Market.
